StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report report published on Thursday. The firm issued a sell rating on the stock.

Separately, Benchmark reiterated a hold rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Trading Up 16.2 %

Shares of VNRX opened at $0.88 on Thursday. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23. The firm has a fifty day simple moving average of $0.64 and a 200 day simple moving average of $0.69. The stock has a market capitalization of $81.32 million, a price-to-earnings ratio of -1.92 and a beta of 1.09.

VolitionRx (NYSE:VNRX) last announced its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.34 million. As a group, research analysts predict that VolitionRx will post -0.31 earnings per share for the current fiscal year.

Insider Buying and Selling at VolitionRx

In other news, Director Guy Archibald Innes purchased 150,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was purchased at an average price of $0.67 per share, for a total transaction of $100,500.00. Following the completion of the purchase, the director now directly owns 406,683 shares in the company, valued at $272,477.61. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 12.80% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.